AlloVir Statistics
Total Valuation
AlloVir has a market cap or net worth of $85.73 million. The enterprise value is -$72.72 million.
| Market Cap | 85.73M |
| Enterprise Value | -72.72M |
Important Dates
The next estimated earnings date is Thursday, May 2, 2024, before market open.
| Earnings Date | May 2, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AlloVir has 114.06 million shares outstanding. The number of shares has increased by 35.75% in one year.
| Shares Outstanding | 114.06M |
| Shares Change (YoY) | +35.75% |
| Shares Change (QoQ) | +0.25% |
| Owned by Insiders (%) | 48.95% |
| Owned by Institutions (%) | 42.91% |
| Float | 38.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.58 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.62, with a Debt / Equity ratio of 0.19.
| Current Ratio | 6.62 |
| Quick Ratio | n/a |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -99.70% and return on invested capital (ROIC) is -115.41%.
| Return on Equity (ROE) | -99.70% |
| Return on Assets (ROA) | -78.90% |
| Return on Capital (ROIC) | -115.41% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.70M |
| Employee Count | 112 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -126,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.26% in the last 52 weeks. The beta is 0.85, so AlloVir's price volatility has been lower than the market average.
| Beta (1Y) | 0.85 |
| 52-Week Price Change | -80.26% |
| 50-Day Moving Average | 0.74 |
| 200-Day Moving Average | 1.71 |
| Relative Strength Index (RSI) | 51.78 |
| Average Volume (30 Days) | 865,282 |
Short Selling Information
The latest short interest is 6.30 million, so 5.53% of the outstanding shares have been sold short.
| Short Interest | 6.30M |
| Short Previous Month | 6.27M |
| Short % of Shares Out | 5.53% |
| Short % of Float | 16.46% |
| Short Ratio (days to cover) | 12.99 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -199.90M |
| Pretax Income | -190.54M |
| Net Income | -190.42M |
| EBITDA | -182.25M |
| EBIT | -190.54M |
| Earnings Per Share (EPS) | -$1.83 |
Balance Sheet
The company has $184.80 million in cash and $27.43 million in debt, giving a net cash position of $157.37 million or $1.38 per share.
| Cash & Cash Equivalents | 184.80M |
| Total Debt | 27.43M |
| Net Cash | 157.37M |
| Net Cash Per Share | $1.38 |
| Equity / Book Value | 145.78M |
| Book Value Per Share | 1.28 |
| Working Capital | 159.27M |
Cash Flow
| Operating Cash Flow | -124.45M |
| Capital Expenditures | n/a |
| Free Cash Flow | -124.45M |
| FCF Per Share | -$1.20 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AlloVir does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -35.75% |
| Shareholder Yield | -35.75% |
| Earnings Yield | -224.96% |
| FCF Yield | -147.02% |
Analyst Forecast
The average price target for AlloVir is $5.88, which is 684.00% higher than the current price. The consensus rating is "Hold".
| Price Target | $5.88 |
| Price Target Difference | 684.00% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |